Mark Warren

6PUBLICATIONS
19CO-AUTHORS
Immunogenetics (incl. genetic immunology)Prosthetics and orthoticsPharmaceutical delivery technologiesExercise physiologyFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 01, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Elena A Christofides, Orlando Puente, Paul Norwood

|Apr 24, 2023
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism.

Nelson B Watts, John P Bilezikian, Henry G Bone

|Mar 09, 2021
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.

Mark Warren, Bruce Bode, Jang I Cho

|Apr 01, 2020
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).

Esteban Jódar, Marie Michelsen, William Polonsky

|May 17, 2018
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.

Bo Ahrén, Stephen L Atkin, Guillaume Charpentier

|Apr 25, 2018
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.

Mark Warren, Louis Chaykin, David Trachtenbarg

Pageof 1

Frequent Collaborators

1 joint publications

Bo Ahrén

1 joint publications

Stephen L Atkin

1 joint publications

Lawrence A Leiter

1 joint publications

Nelson B Watts